Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Offered by National Institutes of Health; applications due January 7, 2028.
Key Facts
- Funder
- National Institutes of Health
- Award amount
- Not specified by funder
- Deadline
- January 7, 2028
- Geography
- United States
- Categories
- Research
- Status
- Open
About This Grant
The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular...
Full requirements and application instructions: official listing.
Similar Open Grants
Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 - Clinical Trial Optional)
National Institutes of Health
Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)
National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
National Institutes of Health
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
National Institutes of Health
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
National Institutes of Health
Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
National Institutes of Health
Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)
National Institutes of Health
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
National Institutes of Health
Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)
National Institutes of Health